Based on a licence from Else Marit Inderberg and Sebastien Wälchli’s group at The Section of Cell Therapy at Oslo University Hospital, the company Zelluna Immunotherapy is developing natural killer cells that are steered by T cell receptors. The aim is to offer different forms of targeted immunotherapy treatments that do not have to be individually tailored for each patient. Zelluna Immunotherapy receives NOK 83 million from investors and the Research Council of Norway to continue its work on this new form of cancer immunotherapy.
Published in major journals, first or last author from Oslo University Hospital.
Viscoelastic haemostatic assay augmented protocols for major trauma haemorrhage (ITACTIC): a randomized, controlled trial
Intensive Care Med (in press)
Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database
Ann Rheum Dis (in press)
Elevated plasma sTIM-3 levels in patients with severe COVID-19
J Allergy Clin Immunol (in press)